Telikibart clinical trials
How each study uses telikibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the telikibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- GR1802 injection
- 7
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test telikibart, phase 3 first.
- May 2027A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.Phase 3 · Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses telikibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.Not yet recruitingPhase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT07199257Written as GR1802 injection
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic RhinitisRecruitingPhase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT07154342Written as GR1802 injection
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe AsthmaRecruitingPhase 2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT06642961Written as GR1802 injection
- Phase III Study of GR1802 Injection in Patients With Atopic DermatitisNot yet recruitingPhase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT06216392Written as GR1802 injection
- The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingPhase 2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT06015243Written as GR1802 injection
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).Active, not recruitingPhase 2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT06315426Written as GR1802 injection
- The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal PolypsActive, not recruitingPhase 2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT05873803Written as GR1802 injection
Codes
What other systems call telikibart · ClinicalTrials.gg INT033143
- UNII (FDA) XLJ7694SEXTELIKIBARTOne source FDA
- NCI Thesaurus C211820TelikibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XLJ7694SEX | TELIKIBART | One source FDA |
| NCI Thesaurus | C211820 | Telikibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.